Opus Point Partners Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Opus Point Partners Management’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-93,805	Closed	-$5.37M	–	48
2018 Q2	$5.37M	Sell	93,805 -93,805	-50%	-$5.11M	11.64%	2
2018 Q1	$10.3M	Buy	187,610 +57,110	+44%	+$3.42M	20.26%	1
2017 Q4	$7.32M	Hold	130,500	–	–	6.33%	2
2017 Q3	$7.99M	Hold	130,500	–	–	7.17%	1
2017 Q2	$6.97M	Buy	130,500 +45,500	+54%	+$2.22M	6.38%	1
2017 Q1	$4.1M	Hold	85,000	–	–	3.04%	11
2016 Q4	$3.39M	Hold	85,000	–	–	2.7%	11
2016 Q3	$4.12M	Buy	+85,000	New	+$4.04M	2.31%	6
2016 Q2	–	Sell	-64,462	Closed	-$2.64M	–	45
2016 Q1	$2.64M	Buy	64,462 +49,543	+332%	+$2.19M	2.04%	22
2015 Q4	$1.07M	Sell	14,919 -17,798	-54%	-$1.19M	0.7%	39
2015 Q3	$1.91M	Sell	32,717 -20,851	-39%	-$1.78M	1.05%	26
2015 Q2	$4.84M	Buy	53,568 +18,000	+51%	+$1.55M	3.83%	4
2015 Q1	$2.82M	Sell	35,568 -40,800	-53%	-$3.03M	2.36%	24
2014 Q4	$4.79M	Buy	+76,368	New	+$4.48M	4.74%	1

Other funds holding BIB

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Howard Capital Management Roswell, Georgia $8.26B AUM 36.73% 1-Year Est. Return

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return

BRC

Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Opus Point Partners Management's BIB Position: Q3 2018 in Review

Opus Point Partners Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2018, closing a stake of 93,805 shares — an estimated $5.37M sold.

Opus Point Partners Management first reported a position in BIB in Q4 2014 and held it in 14 quarters. The position peaked at $10.3M in Q1 2018. 41 funds tracked by Wall St. Rank hold BIB as of Q3 2018.

Opus Point Partners Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2018 after selling out during the quarter.
Opus Point Partners Management sold 93,805 ProShares Ultra NASDAQ Biotechnology shares in Q3 2018, an estimated $5.37M.
Opus Point Partners Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and held it in 14 quarters.
Opus Point Partners Management's ProShares Ultra NASDAQ Biotechnology position peaked at $10.3M in Q1 2018.
41 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2018.

Based on Opus Point Partners Management's 13F filing for Q3 2018, filed 14 Nov 2018.